Bullet Biotechnology

Bullet Bio develops next-generation combination immunotherapies with curative potential, including therapeutic vaccines and multi-specific antibodies.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Menlo Park, CA, USA
  • Currency USD
  • Founded September 2011
  • Employees 3
  • Website

Company Summary

Bullet Bio is developing active immunotherapies that train your immune system to fight disease. Our lead product is a personalized immunotherapy that targets a tumor-specific antigen present on B-cell lymphoma cells. We are pursuing a minimal infrastructure, "virtual" model, focusing on developing products and generating intellectual property. We plan to file our first IND application (the document that enables clinical trials) in 4Q15.


  • Default avatar
    Jim Swartz
    Director, Advisor, co-founder

    Jim Swartz is a Stanford Professor in the Departments of Bioengineering and Chemical Engineering. His lab developed the cell-free protein synthesis technology that produced our initial therapeutic cancer vaccine. Jim has over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. He holds a B.S. from the South Dakota School of Mines and a D.Sc. from M.I.T.

  • Default avatar
    Tom Theriault
    Chief Scientific Officer, co-founder

    Tom Theriault is leading the R&D efforts for Bullet. After getting his PhD from Stanford University, Tom founded a microarray company that was acquired by Incyte Genomics. He continued to work for Incyte for 8 years before entering the world of cancer immunotherapy as VP R&D at Genitope. Tom is excited to apply the lessons from Genitope in developing Bullet’s products.

  • Default avatar
    Sam Saks

    Dr. Saks is an oncologist who was founding CEO of Jazz Pharmaceuticals from 2003 to 2009. Prior to Jazz, Dr. Saks held senior leadership positions in clinical & commercial development at ALZA and J&J. He held clinical research positions in oncology at Schering-Plough, XOMA Corporation and Genentech. Dr. Saks received a B.S. and an M.D. from the University of Illinois and currently serves on the Board of several companies.

  • Default avatar
    Diego Fonstad
    Director, co-founder

    Diego Fonstad is a serial entrepreneur who first cut his teeth in the early days of the internet, then co-founded biotech company Sutro Biopharma. He is a co-founder of Bullet Biotechnology and has also incubated a green building venture and founded, a nonprofit in math and science education. Diego has an AB from Harvard and an MBA from Stanford.

  • 7877e169 e8dc 4549 b08d deabba10875b
    President & CEO, co-founder

    Willie Quinn was one of the first employees at Jazz Pharmaceuticals, participating in strategy development and execution over more than 8 years as Jazz transformed from a raw startup to a public, profitable specialty pharma company. His experience includes being COO and CFO of Novation Biosciences, and managing a portfolio of more than 12 companies at Mobius Venture Capital. Willie has an MBA, an MA, and a BA from Stanford University.


  • Default avatar
    Cooley Godward (Glen Sato & Marya Postner)